Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.45 |
| ▸ | PPID | Q08752 | 1/20 | 0.37 |
| ▸ | BIRC2 | Q13490 | 3/20 | 0.35 |
| ▸ | CAD | P27708 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 2/20 | 0.34 |
| ▸ | METAP1 | P53582 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30420085 | 1.00 | L3MBTL1 (0.47) | L3MBTL1KMT2APOLBNOD1PPID | |
| Hydrochloric Acid SCHEMBL30420185 | 0.99 | L3MBTL1 (0.46) | L3MBTL1KMT2APOLBNOD1PPID | |
| Hydrochloric Acid SCHEMBL31294486 | 0.85 | L3MBTL1 (0.58) | L3MBTL1KMT2APOLBNOD1PPID | |
| SCHEMBL23834159 | 0.83 | NOD1 (0.49) | NOD1 | |
| SCHEMBL20468543 | 0.83 | L3MBTL1 (0.43) | L3MBTL1KMT2APOLBNOD1PPID | |
| SCHEMBL8643638 | 0.83 | PPID (0.49) | PPIDBIRC2CADMETAP2METAP1 | |
| SCHEMBL8643634 | 0.83 | PPID (0.49) | PPIDBIRC2CADMETAP2METAP1 | |
| SCHEMBL25760765 | 0.82 | L3MBTL1 (0.42) | L3MBTL1KMT2APOLBNOD1PPID | |
| SCHEMBL25760733 | 0.82 | L3MBTL1 (0.42) | L3MBTL1KMT2APOLBNOD1PPID | |
| SCHEMBL25518101 | 0.82 | PPID (0.42) | L3MBTL1PPIDBIRC2CADMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | ASNS, GLUL, GNMT | L3MBTL1 397/4885KMT2A 2657/4885POLB 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.